Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$32.87
-0.53-1.59%
At close: -
$32.87
0.000.00%
After Hours: Jun 20, 4:02 PM EDT
Comments
Loading...
Vaxcyte Analyst Ratings and Price Targets | NASDAQ:PCVX | Benzinga
Vaxcyte Inc has a consensus price target of $132.7 based on the ratings of 13 analysts. The high is $175 issued by B of A Securities on February 9, 2024. The low is $60 issued by SVB Leerink on December 16, 2022. The 3 most-recent analyst ratings were released by Needham, Goldman Sachs, and B of A Securities on April 8, 2025, April 1, 2025, and April 1, 2025, respectively. With an average price target of $109 between Needham, Goldman Sachs, and B of A Securities, there's an implied 231.61% upside for Vaxcyte Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Goldman Sachs
B of A Securities
Guggenheim
BTIG
1calculated from analyst ratings
Analyst Ratings for Vaxcyte
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/22/2025 | Buy Now | — | Cantor Fitzgerald | Carter Gould55% | — | Initiates | → Overweight | Get Alert |
| 04/08/2025 | Buy Now | 173.81% | Needham | Joseph Stringer61% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2025 | Buy Now | 204.23% | Goldman Sachs | Chris Shibutani54% | $138 → $100 | Maintains | Buy | Get Alert |
| 04/01/2025 | Buy Now | 316.79% | B of A Securities | Jason Gerberry63% | $157 → $137 | Maintains | Buy | Get Alert |
| 04/01/2025 | Buy Now | 173.81% | Needham | Joseph Stringer61% | $140 → $90 | Maintains | Buy | Get Alert |
| 03/12/2025 | Buy Now | 386.77% | Guggenheim | Seamus Fernandez61% | $160 → $160 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 386.77% | Guggenheim | Seamus Fernandez61% | $160 → $160 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 325.92% | Needham | Joseph Stringer61% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | 386.77% | BTIG | Thomas Shrader40% | $160 → $160 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | -57.41% | Needham | Joseph Stringer61% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 310.71% | Goldman Sachs | Chris Shibutani54% | → $135 | Initiates | → Buy | Get Alert |
| 11/06/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 11/06/2024 | Buy Now | 325.92% | Needham | Joseph Stringer61% | $140 → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/10/2024 | Buy Now | 395.89% | Mizuho | Salim Syed44% | $113 → $163 | Maintains | Outperform | Get Alert |
| 09/04/2024 | Buy Now | 325.92% | B of A Securities | Jason Gerberry63% | $101 → $140 | Maintains | Buy | Get Alert |
| 09/03/2024 | Buy Now | 365.47% | Leerink Partners | David Risinger72% | $106 → $153 | Maintains | Outperform | Get Alert |
| 09/03/2024 | Buy Now | 292.46% | Jefferies | Roger Song36% | $108 → $129 | Maintains | Buy | Get Alert |
| 09/03/2024 | Buy Now | 325.92% | Needham | Joseph Stringer61% | $95 → $140 | Maintains | Buy | Get Alert |
| 09/03/2024 | Buy Now | 386.77% | BTIG | Thomas Shrader40% | $98 → $160 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | 198.14% | BTIG | Thomas Shrader40% | $98 → $98 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 189.02% | Needham | Joseph Stringer61% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 189.02% | Needham | Joseph Stringer61% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2024 | Buy Now | 207.27% | B of A Securities | Jason Gerberry63% | $101 → $101 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 189.02% | Needham | Joseph Stringer61% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 04/10/2024 | Buy Now | 189.02% | Needham | Joseph Stringer61% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 243.78% | Mizuho | Salim Syed44% | $69 → $113 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 189.02% | Needham | Joseph Stringer61% | $73 → $95 | Maintains | Buy | Get Alert |
| 02/09/2024 | Buy Now | 432.4% | B of A Securities | Adam Bergere 1% | $180 → $175 | Maintains | Neutral | Get Alert |
| 02/06/2024 | Buy Now | 179.89% | B of A Securities | Jason Gerberry63% | $80 → $92 | Maintains | Buy | Get Alert |
| 01/02/2024 | Buy Now | 143.38% | B of A Securities | Jason Gerberry63% | $67 → $80 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | 109.92% | Mizuho | Salim Syed44% | → $69 | Initiates | → Buy | Get Alert |
| 11/07/2023 | Buy Now | 76.45% | Needham | Joseph Stringer61% | → $58 | Reiterates | Buy → Buy | Get Alert |
| 10/26/2023 | Buy Now | 538.88% | B of A Securities | Jason Gerberry63% | → $210 | Initiates | → Neutral | Get Alert |
| 08/22/2023 | Buy Now | 112.96% | Cantor Fitzgerald | Louise Chen56% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 103.83% | B of A Securities | Jason Gerberry63% | $66 → $67 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | 76.45% | Needham | Joseph Stringer61% | → $58 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2023 | Buy Now | 76.45% | Needham | Joseph Stringer61% | → $58 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | — | TD Cowen | Boris Peaker49% | — | Initiates | → Outperform | Get Alert |
| 04/18/2023 | Buy Now | 106.88% | B of A Securities | Jason Gerberry63% | $63 → $68 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | 112.96% | Cantor Fitzgerald | Louise Chen56% | $70 → $70 | Maintains | Overweight | Get Alert |
| 02/28/2023 | Buy Now | 91.66% | B of A Securities | Jason Gerberry63% | $64 → $63 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | 97.75% | Guggenheim | Seamus Fernandez61% | $66 → $65 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | 76.45% | Needham | Joseph Stringer61% | → $58 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 189.02% | Needham | Joseph Stringer61% | $73 → $95 | Maintains | Buy | Get Alert |
| 01/03/2023 | Buy Now | 76.45% | Needham | Joseph Stringer61% | $52 → $58 | Maintains | Buy | Get Alert |
| 12/16/2022 | Buy Now | 82.54% | SVB Leerink | David Risinger72% | → $60 | Initiates | → Outperform | Get Alert |
| 12/15/2022 | Buy Now | 100.79% | Guggenheim | Seamus Fernandez61% | → $66 | Initiates | → Buy | Get Alert |
| 11/17/2022 | Buy Now | 109.92% | BTIG | Thomas Shrader40% | → $69 | Initiates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | 112.96% | Cantor Fitzgerald | Louise Chen56% | $55 → $70 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Vaxcyte (PCVX) stock?
The latest price target for Vaxcyte (NASDAQ:PCVX) was reported by Cantor Fitzgerald on April 22, 2025. The analyst firm set a price target for $0.00 expecting PCVX to fall to within 12 months (a possible -100.00% downside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vaxcyte (PCVX)?
The latest analyst rating for Vaxcyte (NASDAQ:PCVX) was provided by Cantor Fitzgerald, and Vaxcyte initiated their overweight rating.
When was the last upgrade for Vaxcyte (PCVX)?
There is no last upgrade for Vaxcyte
When was the last downgrade for Vaxcyte (PCVX)?
There is no last downgrade for Vaxcyte.
When is the next analyst rating going to be posted or updated for Vaxcyte (PCVX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vaxcyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vaxcyte was filed on April 22, 2025 so you should expect the next rating to be made available sometime around April 22, 2026.
Is the Analyst Rating Vaxcyte (PCVX) correct?
While ratings are subjective and will change, the latest Vaxcyte (PCVX) rating was a initiated with a price target of $0.00 to $0.00. The current price Vaxcyte (PCVX) is trading at is $32.87, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
